4‐Methylpyrazole: A Controlled Study of Safety in Healthy Human Subjects after Single, Ascending Doses

Dag Jacobsen, C Simon Sebastian, Rolf Blomstrand, Kenneth E. McMartin

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

4‐Methylpyrazole (4‐MP), an inhibitor of alcohol dehydrogenase, is a possible future drug for the treatment of methanol and ethylene glycol intoxications and the severe ethanol‐disulfiram reaction. Therefore a placebo‐controlled, double‐blind, single‐dose, randomized, sequential, ascending‐dose “Phase I study” was performed in healthy volunteers in order to determine the tolerance of 4‐MP at dose levels of 10 (n= 4), 20 (n= 4), 50 (n= 4), and 100 mg/kg (n= 3). Along with each dose group, there were two placebos except with the 100 mg/kg group where there was only one placebo. In the 10 and 20 mg/kg group there were no side‐effects in any subject. At the 50 mg/kg level, three out of four subjects experienced slight to moderate nausea and dizziness from 0 to 2.5 h after dosing. In the 100 mg/kg group all three subjects reported side‐effects like nausea, dizziness, and vertigo, that were short‐lived in two subjects, but lasted up to 30 h in one subject The study was stopped after evaluation of the latter subject, so fewer subjects were completed in this last group. Despite these subjective side‐effects, there were no significant changes in objective clinical parameters like pulse, blood pressure, body temperature, or blood and urine chemistries. We conclude that at a single dose of 4‐MP (10–20 mg/kg) producing plasma levels within a probable therapeutic range, no side‐effects were attributed to 4‐MP.

Original languageEnglish (US)
Pages (from-to)516-522
Number of pages7
JournalAlcoholism: Clinical and Experimental Research
Volume12
Issue number4
DOIs
StatePublished - Jan 1 1988
Externally publishedYes

Fingerprint

Ethylene Glycol
Alcohol Dehydrogenase
Blood pressure
Dizziness
Nausea
Methanol
Healthy Volunteers
Blood
Placebos
Blood Pressure
Plasmas
Safety
Vertigo
Body Temperature
Pharmaceutical Preparations
Urine
Temperature
Therapeutics

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Toxicology
  • Psychiatry and Mental health

Cite this

4‐Methylpyrazole : A Controlled Study of Safety in Healthy Human Subjects after Single, Ascending Doses. / Jacobsen, Dag; Sebastian, C Simon; Blomstrand, Rolf; McMartin, Kenneth E.

In: Alcoholism: Clinical and Experimental Research, Vol. 12, No. 4, 01.01.1988, p. 516-522.

Research output: Contribution to journalArticle

@article{391e1019a70f4ceb92f2583907ec778a,
title = "4‐Methylpyrazole: A Controlled Study of Safety in Healthy Human Subjects after Single, Ascending Doses",
abstract = "4‐Methylpyrazole (4‐MP), an inhibitor of alcohol dehydrogenase, is a possible future drug for the treatment of methanol and ethylene glycol intoxications and the severe ethanol‐disulfiram reaction. Therefore a placebo‐controlled, double‐blind, single‐dose, randomized, sequential, ascending‐dose “Phase I study” was performed in healthy volunteers in order to determine the tolerance of 4‐MP at dose levels of 10 (n= 4), 20 (n= 4), 50 (n= 4), and 100 mg/kg (n= 3). Along with each dose group, there were two placebos except with the 100 mg/kg group where there was only one placebo. In the 10 and 20 mg/kg group there were no side‐effects in any subject. At the 50 mg/kg level, three out of four subjects experienced slight to moderate nausea and dizziness from 0 to 2.5 h after dosing. In the 100 mg/kg group all three subjects reported side‐effects like nausea, dizziness, and vertigo, that were short‐lived in two subjects, but lasted up to 30 h in one subject The study was stopped after evaluation of the latter subject, so fewer subjects were completed in this last group. Despite these subjective side‐effects, there were no significant changes in objective clinical parameters like pulse, blood pressure, body temperature, or blood and urine chemistries. We conclude that at a single dose of 4‐MP (10–20 mg/kg) producing plasma levels within a probable therapeutic range, no side‐effects were attributed to 4‐MP.",
author = "Dag Jacobsen and Sebastian, {C Simon} and Rolf Blomstrand and McMartin, {Kenneth E.}",
year = "1988",
month = "1",
day = "1",
doi = "10.1111/j.1530-0277.1988.tb00235.x",
language = "English (US)",
volume = "12",
pages = "516--522",
journal = "Alcoholism: Clinical and Experimental Research",
issn = "0145-6008",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - 4‐Methylpyrazole

T2 - A Controlled Study of Safety in Healthy Human Subjects after Single, Ascending Doses

AU - Jacobsen, Dag

AU - Sebastian, C Simon

AU - Blomstrand, Rolf

AU - McMartin, Kenneth E.

PY - 1988/1/1

Y1 - 1988/1/1

N2 - 4‐Methylpyrazole (4‐MP), an inhibitor of alcohol dehydrogenase, is a possible future drug for the treatment of methanol and ethylene glycol intoxications and the severe ethanol‐disulfiram reaction. Therefore a placebo‐controlled, double‐blind, single‐dose, randomized, sequential, ascending‐dose “Phase I study” was performed in healthy volunteers in order to determine the tolerance of 4‐MP at dose levels of 10 (n= 4), 20 (n= 4), 50 (n= 4), and 100 mg/kg (n= 3). Along with each dose group, there were two placebos except with the 100 mg/kg group where there was only one placebo. In the 10 and 20 mg/kg group there were no side‐effects in any subject. At the 50 mg/kg level, three out of four subjects experienced slight to moderate nausea and dizziness from 0 to 2.5 h after dosing. In the 100 mg/kg group all three subjects reported side‐effects like nausea, dizziness, and vertigo, that were short‐lived in two subjects, but lasted up to 30 h in one subject The study was stopped after evaluation of the latter subject, so fewer subjects were completed in this last group. Despite these subjective side‐effects, there were no significant changes in objective clinical parameters like pulse, blood pressure, body temperature, or blood and urine chemistries. We conclude that at a single dose of 4‐MP (10–20 mg/kg) producing plasma levels within a probable therapeutic range, no side‐effects were attributed to 4‐MP.

AB - 4‐Methylpyrazole (4‐MP), an inhibitor of alcohol dehydrogenase, is a possible future drug for the treatment of methanol and ethylene glycol intoxications and the severe ethanol‐disulfiram reaction. Therefore a placebo‐controlled, double‐blind, single‐dose, randomized, sequential, ascending‐dose “Phase I study” was performed in healthy volunteers in order to determine the tolerance of 4‐MP at dose levels of 10 (n= 4), 20 (n= 4), 50 (n= 4), and 100 mg/kg (n= 3). Along with each dose group, there were two placebos except with the 100 mg/kg group where there was only one placebo. In the 10 and 20 mg/kg group there were no side‐effects in any subject. At the 50 mg/kg level, three out of four subjects experienced slight to moderate nausea and dizziness from 0 to 2.5 h after dosing. In the 100 mg/kg group all three subjects reported side‐effects like nausea, dizziness, and vertigo, that were short‐lived in two subjects, but lasted up to 30 h in one subject The study was stopped after evaluation of the latter subject, so fewer subjects were completed in this last group. Despite these subjective side‐effects, there were no significant changes in objective clinical parameters like pulse, blood pressure, body temperature, or blood and urine chemistries. We conclude that at a single dose of 4‐MP (10–20 mg/kg) producing plasma levels within a probable therapeutic range, no side‐effects were attributed to 4‐MP.

UR - http://www.scopus.com/inward/record.url?scp=0023764130&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023764130&partnerID=8YFLogxK

U2 - 10.1111/j.1530-0277.1988.tb00235.x

DO - 10.1111/j.1530-0277.1988.tb00235.x

M3 - Article

C2 - 3056073

AN - SCOPUS:0023764130

VL - 12

SP - 516

EP - 522

JO - Alcoholism: Clinical and Experimental Research

JF - Alcoholism: Clinical and Experimental Research

SN - 0145-6008

IS - 4

ER -